{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:41:40Z","timestamp":1756572100374},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,15]]},"DOI":"10.7759\/cureus.50581","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T16:05:01Z","timestamp":1702656301000},"source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of Latent Tuberculosis Infection Among Rheumatology Patients and Management Practices in the United Arab Emirates: A Single-Center Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Shamma","family":"Al Nokhatha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"AlKindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Alfalasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merna","family":"Abdelsalhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"AlKhyeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad  R","family":"Alsaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management","year":"2018","unstructured":"Latent Tuberculosis Infection. Updated and Consolidated Guidelines for Programmatic Management. World Health Organization, Geneva; 2018."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6680651","article-title":"Prevalence of latent tuberculosis infection in the Middle East and North Africa: a systematic review","volume":"2021","author":"Barry M","year":"2021","unstructured":"Barry M. Prevalence of latent tuberculosis infection in the Middle East and North Africa: a systematic review. Pulm Med. 2021, 2021:6680651. 10.1155\/2021\/6680651","journal-title":"Pulm Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00013409","article-title":"Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs","volume":"34","author":"Sester U","year":"2009","unstructured":"Sester U, Wilkens H, van Bentum K, Singh M, Sybrecht GW, Sch\u00e4fers HJ, Sester M. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J. 2009, 34:702-10. 10.1183\/09031936.00013409","journal-title":"Eur Respir J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0026-2016","article-title":"Biologic agents and tuberculosis","volume":"4","author":"Dobler CC","year":"2016","unstructured":"Dobler CC. Biologic agents and tuberculosis. Microbiol Spectr. 2016, 4:10.1128\/microbiolspec.TNMI7-0026-2016","journal-title":"Microbiol Spectr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon WG","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Symmons DP. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010, 69:522-8. 10.1136\/ard.2009.118935","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1590\/1806-3713\/e20190023","article-title":"Latent tuberculosis infection in patients with rheumatic diseases","volume":"45","author":"Anton C","year":"2019","unstructured":"Anton C, Machado FD, Ramirez JM, et al.. Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol. 2019, 45:e20190023. 10.1590\/1806-3713\/e20190023","journal-title":"J Bras Pneumol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04929-w","article-title":"Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry","volume":"41","author":"Oulkadi L","year":"2021","unstructured":"Oulkadi L, Rostom S, Hmamouchi I, et al.. Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry. Rheumatol Int. 2021, 41:1625-31. 10.1007\/s00296-021-04929-w","journal-title":"Rheumatol Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00814-14","article-title":"Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results","volume":"52","author":"Tebruegge M","year":"2014","unstructured":"Tebruegge M, de Graaf H, Sukhtankar P, et al.. Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results. J Clin Microbiol. 2014, 52:2694-7. 10.1128\/JCM.00814-14","journal-title":"J Clin Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245888","article-title":"Tuberculosis in the elderly","volume":"10","author":"Caraux-Paz P","year":"2021","unstructured":"Caraux-Paz P, Diamantis S, de Wazi\u00e8res B, Gallien S. Tuberculosis in the elderly. J Clin Med. 2021, 10:10.3390\/jcm10245888","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204960","article-title":"Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?","volume":"74","author":"Arkema EV","year":"2015","unstructured":"Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?. Ann Rheum Dis. 2015, 74:1212-7. 10.1136\/annrheumdis-2013-204960","journal-title":"Ann Rheum Dis"},{"key":"ref11","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona L","year":"2003","unstructured":"Carmona L, Hern\u00e1ndez-Garc\u00eda C, Vadillo C, et al.. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003, 30:1436-9.","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S258235","article-title":"Activity disease in SLE patients affected IFN-\u03b3 in the IGRA results","volume":"13","author":"Maharani W","year":"2020","unstructured":"Maharani W, Ratnaningsih DF, Utami F, Yulianto FA, Dewina A, Hamijoyo L, Atik N. Activity disease in SLE patients affected IFN-\u03b3 in the IGRA results\r\n. J Inflamm Res. 2020, 13:433-9. 10.2147\/JIR.S258235","journal-title":"J Inflamm Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310397966","article-title":"Interferon-gamma release assay for diagnosing Mycobacterium tuberculosis infections in patients with systemic lupus erythematosus","volume":"20","author":"Takeda N","year":"2011","unstructured":"Takeda N, Nojima T, Terao C, et al.. Interferon-gamma release assay for diagnosing Mycobacterium tuberculosis infections in patients with systemic lupus erythematosus. Lupus. 2011, 20:792-800. 10.1177\/0961203310397966","journal-title":"Lupus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis GE","year":"2023","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, et al.. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023, 82:742-53. 10.1136\/ard-2022-223335","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2021.05.011","article-title":"Differentiating between active and latent tuberculosis with chest computed tomography","volume":"102","author":"Bommart S","year":"2021","unstructured":"Bommart S, Charriot J, Nagot N, et al.. Differentiating between active and latent tuberculosis with chest computed tomography. Diagn Interv Imaging. 2021, 102:605-10. 10.1016\/j.diii.2021.05.011","journal-title":"Diagn Interv Imaging"},{"key":"ref16","unstructured":"Centers for Disease Control and Prevention. IGRAs\u2014blood tests for TB infection fact sheet. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/testing\/igra.htm."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22454","article-title":"Evaluating indeterminate interferon-\u03b3-release assay results in patients with chronic inflammatory diseases receiving immunosuppressive therapy","volume":"67","author":"Calabrese C","year":"2015","unstructured":"Calabrese C, Overman RA, Dusetzina SB, Hajj-Ali RA. Evaluating indeterminate interferon-\u03b3-release assay results in patients with chronic inflammatory diseases receiving immunosuppressive therapy. Arthritis Care Res (Hoboken). 2015, 67:1063-9. 10.1002\/acr.22454","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong SH","year":"2016","unstructured":"Wong SH, Gao Q, Tsoi KK, et al.. Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016, 71:64-72. 10.1136\/thoraxjnl-2015-207811","journal-title":"Thorax"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay","volume":"67","author":"Matulis G","year":"2008","unstructured":"Matulis G, J\u00fcni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis. 2008, 67:84-90. 10.1136\/ard.2007.070789","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini F","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries. J Rheumatol Suppl. 2014, 91:56-64. 10.3899\/jrheum.140103","journal-title":"J Rheumatol Suppl"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022445","article-title":"Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines","volume":"8","author":"Hasan T","year":"2018","unstructured":"Hasan T, Au E, Chen S, Tong A, Wong G. Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open. 2018, 8:e022445. 10.1136\/bmjopen-2018-022445","journal-title":"BMJ Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000712","article-title":"The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement","volume":"40","author":"Bumbacea D","year":"2012","unstructured":"Bumbacea D, Arend SM, Eyuboglu F, et al.. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J. 2012, 40:990-1013. 10.1183\/09031936.00000712","journal-title":"Eur Respir J"},{"key":"ref23","article-title":"European Centre for Disease Prevention and Control: Use of Interferon-Gamma Release Assays in Support of TB Diagnosis","year":"2011","unstructured":"European Centre for Disease Prevention and Control. Use of Interferon-Gamma Release Assays in Support of TB Diagnosis. ECDC, Stockholm; 2011."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling TR","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, et al.. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020, 69:1-11. 10.15585\/mmwr.rr6901a1","journal-title":"MMWR Recomm Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies D","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, et al.. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults\r\n. N Engl J Med. 2018, 379:440-53. 10.1056\/NEJMoa1714283","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1157\/13102264","article-title":"Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial (Article in Spanish)","volume":"25","author":"Geijo MP","year":"2007","unstructured":"Geijo MP, Herranz CR, Va\u00f1o D, Garc\u00eda AJ, Garc\u00eda M, Dimas JF. Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial (Article in Spanish). Enferm Infecc Microbiol Clin. 2007, 25:300-4. 10.1157\/13102264","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling TR","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, et al.. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011, 365:2155-66. 10.1056\/NEJMoa1104875","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key207","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-executive summary","volume":"58","author":"Holroyd CR","year":"2019","unstructured":"Holroyd CR, Seth R, Bukhari M, et al.. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-executive summary. Rheumatology (Oxford). 2019, 58:220-6. 10.1093\/rheumatology\/key207","journal-title":"Rheumatology (Oxford)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh JA","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, et al.. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012, 64:625-39. 10.1002\/acr.21641","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/203934-prevalence-of-latent-tuberculosis-infection-among-rheumatology-patients-and-management-practices-in-the-united-arab-emirates-a-single-center-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:07Z","timestamp":1707509407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/203934-prevalence-of-latent-tuberculosis-infection-among-rheumatology-patients-and-management-practices-in-the-united-arab-emirates-a-single-center-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.50581","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,15]]}}}